COVID-19

Home/ COVID-19

ESID COVID-19 Statement, March 2022

Since the start of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, there has been rapid progress with understanding disease, clinical phenotypes and biology, improving treatment and implementing vaccination trials. Data is accumulating about the impact of COVID-19 for patients with Inborn Errors of Immunity (IEI). The purpose of this statement is to summarise our state of knowledge and set out ESID’s current guidance for professionals in the IEI community in Europe. We will update this statement as evidence emerges. 

IPOPI – ESID Joint Statement: The use of monoclonal antibody treatment for patients with PID in the context of the COVID-19 pandemic

 IPOPI ESID Statement IPOPI – ESID Joint Statement The use of monoclonal antibody treatment for patients with PID in the context of the COVID-19 pandemic 11 November 2021 The role of monoclonal antibody (mAb or moAb) therapies in the treatme...

Joint statement on the current epidemics of new Coronavirus

Together with IPOPI, INGID, APSID, ASID, ARAPID, CIS, LASID, SEAPID we have worked on a joint statement to provide guidance in advising patients with primary immunodeficiency under our care in the current COVID-19 context.

Independent study:SARS-CoV-2 infection in patients with GATA2 deficiency

Dear ESID Member,

We and ESID Board want to pay your immediate attention to an ongoing independent survey by the COVID Human Genetic Effort on the clinical characteristics of SARS-CoV-2 infection in patients with GATA2 deficiency
We consider this an important and timely survey. If your center has such patients,  please consider, whether your center could participate in it.

Independent Survey: SARS-CoV-2 infection in patients with IRAK-4 or MyD88 deficiencies

Dear ESID Member, We at ESID Board want to pay your immediate attention to an ongoing independent survey by the COVID Human Genetic Effort on the clinical characteristics of SARS-CoV-2 infection in patients with IRAK-4 or MyD88 deficiencies. We...

May 2021: Managing COVID in patients with Type 1 IFN pathway defects

May Webinar

Date: Tuesday 18th May

Time: 17:30-18:30 CET